Biomarker-guided therapies in heart failure: A forum for unified strategies

Mona Fiuzat; Christopher M. O'Connor; Francois Gueyffier; Alice M. Mascette; Nancy L. Geller; Alexandre Mebazaa; Adriaan A. Voors; Kirkwood F. Adams; Ileana L. Piña; Ludwig Neyses; Pieter Muntendam; G. Michael Felker; Bertram Pitt; Faiez Zannad; Michael R. Bristow

doi:10.1016/j.cardfail.2013.05.012

Biomarker-guided therapies in heart failure: A forum for unified strategies

Mona Fiuzat, Christopher M. O'Connor, Francois Gueyffier, Alice M. Mascette, Nancy L. Geller, Alexandre Mebazaa, Adriaan A. Voors, Kirkwood F. Adams, Ileana L. Piña, Ludwig Neyses, Pieter Muntendam, G. Michael Felker, Bertram Pitt, Faiez Zannad, Michael R. Bristow

Research output: Contribution to journal › Article › peer-review

Abstract

The complexity of standard medical treatment for heart failure is growing, and such therapy typically involves 5 or more different medications. Given these pressures, there is increasing interest in harnessing cardiovascular biomarkers for clinical application to more effectively guide diagnosis, risk stratification, and therapy. It may be possible to realize an era of personalized medicine for heart failure treatment in which therapy is optimized and costs are controlled. The direct mechanistic coupling of biologic processes and therapies achieved in cancer treatment remains elusive in heart failure. Recent clinical trials and meta-analyses of biomarkers in heart failure have produced conflicting evidence. In this article, which comprises a summary of discussions from the Global Cardiovascular Clinical Trialists Forum held in Paris, France, we offer a brief overview of the background and rationale for biomarker testing in heart failure, describe opportunities and challenges from a regulatory perspective, and summarize current positions from government agencies in the United States and European Union. © 2013 Elsevier Inc. All rights reserved.

Original language	English
Pages (from-to)	592-599
Number of pages	7
Journal	Journal of Cardiac Failure
Volume	19
Issue number	8
DOIs	https://doi.org/10.1016/j.cardfail.2013.05.012
Publication status	Published - Aug 2013

Keywords

biologic markers
cardiovascular diseases
clinical trials
Pharmacogenetics

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cardfail.2013.05.012

Cite this

Fiuzat, M., O'Connor, C. M., Gueyffier, F., Mascette, A. M., Geller, N. L., Mebazaa, A., Voors, A. A., Adams, K. F., Piña, I. L., Neyses, L., Muntendam, P., Felker, G. M., Pitt, B., Zannad, F., & Bristow, M. R. (2013). Biomarker-guided therapies in heart failure: A forum for unified strategies. Journal of Cardiac Failure, 19(8), 592-599. https://doi.org/10.1016/j.cardfail.2013.05.012

@article{b46fd93e8f144c5583d3982c8f9200af,

title = "Biomarker-guided therapies in heart failure: A forum for unified strategies",

abstract = "The complexity of standard medical treatment for heart failure is growing, and such therapy typically involves 5 or more different medications. Given these pressures, there is increasing interest in harnessing cardiovascular biomarkers for clinical application to more effectively guide diagnosis, risk stratification, and therapy. It may be possible to realize an era of personalized medicine for heart failure treatment in which therapy is optimized and costs are controlled. The direct mechanistic coupling of biologic processes and therapies achieved in cancer treatment remains elusive in heart failure. Recent clinical trials and meta-analyses of biomarkers in heart failure have produced conflicting evidence. In this article, which comprises a summary of discussions from the Global Cardiovascular Clinical Trialists Forum held in Paris, France, we offer a brief overview of the background and rationale for biomarker testing in heart failure, describe opportunities and challenges from a regulatory perspective, and summarize current positions from government agencies in the United States and European Union. {\textcopyright} 2013 Elsevier Inc. All rights reserved.",

keywords = "biologic markers, cardiovascular diseases, clinical trials, Pharmacogenetics",

author = "Mona Fiuzat and O'Connor, {Christopher M.} and Francois Gueyffier and Mascette, {Alice M.} and Geller, {Nancy L.} and Alexandre Mebazaa and Voors, {Adriaan A.} and Adams, {Kirkwood F.} and Pi{\~n}a, {Ileana L.} and Ludwig Neyses and Pieter Muntendam and Felker, {G. Michael} and Bertram Pitt and Faiez Zannad and Bristow, {Michael R.}",

year = "2013",

month = aug,

doi = "10.1016/j.cardfail.2013.05.012",

language = "English",

volume = "19",

pages = "592--599",

journal = "Journal of Cardiac Failure",

issn = "1071-9164",

publisher = "Elsevier BV",

number = "8",

}

TY - JOUR

T1 - Biomarker-guided therapies in heart failure: A forum for unified strategies

AU - Fiuzat, Mona

AU - O'Connor, Christopher M.

AU - Gueyffier, Francois

AU - Mascette, Alice M.

AU - Geller, Nancy L.

AU - Mebazaa, Alexandre

AU - Voors, Adriaan A.

AU - Adams, Kirkwood F.

AU - Piña, Ileana L.

AU - Neyses, Ludwig

AU - Muntendam, Pieter

AU - Felker, G. Michael

AU - Pitt, Bertram

AU - Zannad, Faiez

AU - Bristow, Michael R.

PY - 2013/8

Y1 - 2013/8

N2 - The complexity of standard medical treatment for heart failure is growing, and such therapy typically involves 5 or more different medications. Given these pressures, there is increasing interest in harnessing cardiovascular biomarkers for clinical application to more effectively guide diagnosis, risk stratification, and therapy. It may be possible to realize an era of personalized medicine for heart failure treatment in which therapy is optimized and costs are controlled. The direct mechanistic coupling of biologic processes and therapies achieved in cancer treatment remains elusive in heart failure. Recent clinical trials and meta-analyses of biomarkers in heart failure have produced conflicting evidence. In this article, which comprises a summary of discussions from the Global Cardiovascular Clinical Trialists Forum held in Paris, France, we offer a brief overview of the background and rationale for biomarker testing in heart failure, describe opportunities and challenges from a regulatory perspective, and summarize current positions from government agencies in the United States and European Union. © 2013 Elsevier Inc. All rights reserved.

AB - The complexity of standard medical treatment for heart failure is growing, and such therapy typically involves 5 or more different medications. Given these pressures, there is increasing interest in harnessing cardiovascular biomarkers for clinical application to more effectively guide diagnosis, risk stratification, and therapy. It may be possible to realize an era of personalized medicine for heart failure treatment in which therapy is optimized and costs are controlled. The direct mechanistic coupling of biologic processes and therapies achieved in cancer treatment remains elusive in heart failure. Recent clinical trials and meta-analyses of biomarkers in heart failure have produced conflicting evidence. In this article, which comprises a summary of discussions from the Global Cardiovascular Clinical Trialists Forum held in Paris, France, we offer a brief overview of the background and rationale for biomarker testing in heart failure, describe opportunities and challenges from a regulatory perspective, and summarize current positions from government agencies in the United States and European Union. © 2013 Elsevier Inc. All rights reserved.

KW - biologic markers

KW - cardiovascular diseases

KW - clinical trials

KW - Pharmacogenetics

U2 - 10.1016/j.cardfail.2013.05.012

DO - 10.1016/j.cardfail.2013.05.012

M3 - Article

C2 - 23910590

SN - 1071-9164

VL - 19

SP - 592

EP - 599

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

IS - 8

ER -

Biomarker-guided therapies in heart failure: A forum for unified strategies

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this